Loading
A phase 3 trial of Tisagenlecleucel, Lenalidomide, Rituximab in follicular lymphoma, run by Novartis Pharmaceuticals, active and no longer recruiting.
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma is a phase 3 interventional study registered as NCT05888493 by Novartis Pharmaceuticals, with 109 participants enrolled, started 2023-10-02 and due to reach its primary completion in 2028-07-25. Interventions recorded: Tisagenlecleucel, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles., Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or prednisolone (R-CHOP) in 21-day cycles for 6 to 8 cycles, Lymphodepleting chemotherapy, Corticosteroids and/or Radiation (Bridging therapy). Conditions listed: Follicular Lymphoma (FL). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lenalidomide, Rituximab, Follicular lymphoma, Doxorubicin.
Shares Lenalidomide, Vincristine, Rituximab, Follicular lymphoma.
Shares Lenalidomide, Vincristine, Rituximab, Follicular lymphoma.
Shares Vincristine, Rituximab, Follicular lymphoma, Doxorubicin.
Shares Vincristine, Rituximab, Follicular lymphoma, Doxorubicin.
Shares Vincristine, Rituximab, Follicular lymphoma, Doxorubicin.
Shares Lenalidomide, Vincristine, Rituximab, Follicular lymphoma.
Shares Lenalidomide, Vincristine, Rituximab, Doxorubicin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/